Keywords
external beam partial breast irradiation
doses from 35 to 38.5 Gy delivered in one week
How to Cite
Abstract
Objective: In this study, our purpose was to demonstrate the feasibility and effectiveness of external beam partial breast irradiation (PBI) in patients with early-stage breast cancer treated with breast-conserving surgery.
Methods: 100 patients were treated with PBI with doses ranging from 35 to 38.5 Gy, in 10 fractions b.i.d. All patients were treated with four non-coplanar fields. The clinical tumor volume was well encompassed within the isodose line of 100 % as well as the planning target volume which was within the isodose line of 95 %.
Results: The median follow-up was of 54.3 months. The treatment was well tolerated, with no more than grade I toxicity. So far, there has been one patient with local and axillar recurrence.
Conclusions: In our experience, the treatment was well tolerated with low toxicity and with good results, in a shorter treatment time, with the economical benefits this has, especially for populations in developing countries.
Veronesi U, Cascinelli N, Mariani L,
Greco M et al. Twenty-year follow-up
of a randomized study comparing breastconserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227-32.
Fischer B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-41.
Clark RM, Whelan T, Levine M et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88:1659-64.
Holli K, Saaristo R, Isola J et al. Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer. 2001;84:429-38.
Liljergen G, Holmberg L, Bergh J et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17:2326-33.
Fisher ER, Dignam J, Tan-Chiu E et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86:429-38.
King TA, Bolton JS, Kuske RR et al. Long term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for (Tis,1,2) breast cancer. Am J Surg. 2000;180:299-304.
Vicini FA, Remouchamps V, Wallace M et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conservative surgery. Int J Radia Oncol Biol and Phys. 2003;57:1247-53.
Formenti SC, Rosenstein B. Skinner KA et al. T1 stage breast cancer, adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients-pilot feasibility study. Radiology. 2002;222:171-8.
Orecchia R, Ciocca M, Lazzari R et al. Intraoperative radiation therapy with electrons in early stage breast cancer. Breast J. 2003;12:483-90.
Norris D, Thomas J. Upgrade on NSABPB39/ RTOG Clinical Trial: comparating partial to whole breast irradiation therapy. Oncology Issues [internet]. 2008 Jan-Feb:20-1. 2008. Available from: http://accc-cancer.org/oncology_issues/articles/janfeb08/norris.pdf.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.